Results 1 to 10 of about 1,481 (180)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report [PDF]

Therapeutic Advances in Psychopharmacology, 2021
Functional neurological disorder (FND) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs (either motor or sensory) that cannot be explained by any known medical or mental disease.
Júlia Vendrell-Serres, Óscar Soto-Angona, Amanda Rodríguez-Urrutia, Gara Arteaga-Henríquez, Josep A. Ramos-Quiroga   +4 more
doaj   +8 more sources

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study [PDF]

Frontiers in Psychiatry
IntroductionTreatment resistant depression (TRD) affects approximately 10–30% of patients with major depressive disorder, and most patients with TRD do not respond to real-world treatments (RWT).
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Benoît Rive, Yordan Godinov, Siobhán Mulhern-Haughey   +4 more
doaj   +7 more sources

Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science [PDF]

Clinical and Translational Science
Major depressive disorder (MDD) imposes a substantial burden worldwide, with treatment‐resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDSI) representing two of the most severe clinical challenges ...
Matthijs W. van Hoogdalem, Dong‐Jing Fu, Wayne C. Drevets, Peter N. Zannikos   +3 more
doaj   +3 more sources

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release [PDF]

European Psychiatry
Background Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits.
Andreas Reif, Bernhard T. Baune, Jozefien Buyze, Anthony J. Cleare, Shaun Johnson, Yerkebulan Kambarov, Nigel Olisa, Falk Schuster, Christian von Holt, Tamara Werner-Kiechle, Eduard Vieta   +10 more
doaj   +5 more sources

Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report [PDF]

Pharmaceuticals
Background/Objectives: Ketamine/esketamine has a rapid/robust antidepressant effect on treatment-resistant depression (TRD). However, its long-term cognitive effects remain unclear.
Matildes de Freitas Menezes Sobreiro, Paulo Sergio Panse Silveira, Vitor Breseghello Cavenaghi, Leandro Paulino da Costa, Bruno Pinatti Ferreira de Souza, Rachel Emy Straus Takahashi, Renato Vianna Marotta Starek, José Oliveira Siqueira, Renerio Fraguas   +8 more
doaj   +4 more sources

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression [PDF]

Journal of Comparative Effectiveness Research
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials &
Kristin Clemens, Amanda Teeple, Benoit Rive, Noam Kirson, Urvi Desai, Jason Doran, Diab Eid, Alice Qu, Hannah Bowrey, Kruti Joshi   +9 more
doaj   +3 more sources

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray [PDF]

Neurology and Therapy
Introduction While the literature on esketamine use in commercially insured patients with treatment-resistant depression (TRD) is growing, data on Medicaid beneficiaries remain limited.
Kristin Clemens, Maryia Zhdanava, Amanda Teeple, Arthur Voegel, Aditi Shah, Hannah E. Bowrey, Anabelle Tardif-Samson, Dominic Pilon, Kruti Joshi   +8 more
doaj   +3 more sources

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial [PDF]

European Psychiatry, 2023
Introduction Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88).
A. Reif, A. E. Anıl Yağcıoğlu, A. Luts, T. Messer, R. Nielsen, J. Buyze, T. Ito, Y. Kambarov, S. Mulhern Haughey, B. Rive, I. Usankova, C. von Holt, Y. Godinov   +12 more
doaj   +6 more sources

Challenges for esketamine nasal spray in China: use and management [PDF]

Frontiers in Pharmacology
Jianhong Wu, Jun Gu, Linghe Qiu, Xin Jin, Zhenhe Zhou   +4 more
doaj   +4 more sources

Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel [PDF]

Annals of General Psychiatry, 2023
Background Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants.
Giuseppe Maina, Marina Adami, Giuseppe Ascione, Emi Bondi, Domenico De Berardis, Dario Delmonte, Silvia Maffezzoli, Giovanni Martinotti, Alessandra Nivoli, Elena Ottavianelli, the Delphi Panel Collaboration Group, Andrea Fagiolini   +11 more
doaj   +9 more sources